Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques

Blood. 2018 Aug 9;132(6):662-666. doi: 10.1182/blood-2018-05-846428. Epub 2018 Jun 28.

Authors

Anandani Nellan^{1

2}, Cynthia M Lester McCully³, Rafael Cruz Garcia³, Nalini Jayaprakash³, Brigitte C Widemann³, Daniel W Lee⁴, Katherine E Warren³

Affiliations

¹ Department of Pediatrics, University of Colorado, Denver Anschutz Medical Center, Aurora, CO.
² Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Aurora, CO.
³ Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; and.
⁴ Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Virginia, Charlottesville, VA.

No abstract available

Publication types

Comparative Study
Letter
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Intranasal
Administration, Intravenous
Animals
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / blood
Antibodies, Monoclonal, Humanized / cerebrospinal fluid
Antibodies, Monoclonal, Humanized / pharmacokinetics*
Area Under Curve
Blood-Brain Barrier
Half-Life
Infusions, Intraventricular
Macaca mulatta
Male
Metabolic Clearance Rate

Substances

Antibodies, Monoclonal, Humanized
tocilizumab